Additionally, EUP-SeNP treatment can effectively inhibit lipopolysaccharide-induced activation of the Toll-like receptor-4/NF-κB signaling pathway in IEC lines, suggesting their potential use in the clinical treatment of IBD [236]. Here, NFKB1 is linked to irritable bowel syndrome.